Country success stories in GAP

Countries that had no local H1N1 pandemic vaccine production

MEXICO
Funded through GAP since: 2007
Planned vaccine registration: 2011
Local funds attracted: US$ 115.8 m
Vaccine technology transferred: Inactivated split vaccine
Annual seasonal inactivated IV doses required by national programme: 20 m
Projected annual production (doses) in 2015: 50 m

IRAN
Funded through GAP since: 2009
Planned vaccine registration: > 2012
Local funds attracted: US$ 1.4 m
Vaccine technology transferred: Inactivated whole virion
Annual seasonal inactivated IV doses required by national programme: 0.4 m
Projected annual production (doses) in 2015: 0.5 m

THAILAND
Funded through GAP since: 2007
Planned vaccine registration: 2012
Local funds attracted: US$ 31.2 m
Vaccine technology transferred: Subunit inactivated vaccine & LAIV
Annual seasonal inactivated IV doses required by national programme: 0.6 m
Projected annual production (doses) in 2015: 1 m

INDONESIA
Funded through GAP since: 2007
Planned vaccine registration for vaccine bulk produced locally (local H1N1 vaccine already approved): 2011
Local funds attracted: US$ 167.2 m
Vaccine technology transferred: Inactivated whole virion
Annual seasonal inactivated IV doses required by national programme: 0.2 m
Projected annual production (doses) in 2015: 4 m

Viet Nam
Funded through GAP since: 2007
Planned vaccine registration: 2012
Local funds attracted: US$ 6.3 m
Vaccine technology transferred: Inactivated whole virion
Projected annual production (doses) in 2015: 1 m
H1N1 pandemic inactivated IV (produced by VчьN/2009): 0.005 m

BRAZIL
Funded through GAP since: 2007
Planned vaccine registration: 2011
Local funds attracted: US$ 94.9 m
Vaccine technology transferred: Inactivated split vaccine
Annual seasonal inactivated IV doses required by national programme: 22 m
Projected annual production (doses) in 2015: 58 m

EGYPT
Funded through GAP since: 2009
Planned vaccine registration: > 2012
Local funds attracted: US$ 6.8 m
Vaccine technology transferred: Inactivated whole virion
Annual seasonal inactivated IV doses required by national programme: 0.55 m
Projected annual production (doses) in 2015: 1.5 m

SERBIA
Funded through GAP since: 2009
Planned vaccine registration: 2011
Local funds attracted: US$ 4.9 m
Vaccine technology transferred: Inactivated whole virion
Annual seasonal inactivated IV doses required by national programme: 0.4 m
Projected annual production (doses) in 2015: 2 m

World Health Organization